DBV Technologies | DBVT - Pre Tax Profit


DBV Technologies reported $-47.4M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 3.98M 22.34M Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Amarin USD -852K 7.26M Dec/2025
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
DBV Technologies USD -47.4M 14.24M Mar/2026
Esperion Therapeutics USD 63.67M 95M Dec/2025
Galectin Therapeutics USD -12.37M 880K Jun/2024
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Incyte USD 343.6M 46.34M Mar/2026
Insmed USD -162.1M 164.84M Mar/2026
Ionis Pharmaceuticals USD -93M 135M Mar/2026
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
United Therapeutics USD 444M 6M Dec/2025